12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

FDA approved the Stratify JCV Antibody ELISA test to stratify the risk of developing progressive multifocal leukoencephalopathy (PML) in patients receiving autoimmune drug Tysabri natalizumab. The agency also approved a corresponding...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >